ArticleFrontiers in pharmacology2022
Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Clinical outcomes of immune checkpoint inhibitor combined with other targeted or immunological therapy regimens for the treatment of advanced bile tract cancer: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.Frontiers in immunology · 2023Pooled it
- Adjuvant tislelizumab, lenvatinib, and capecitabine for resected biliary tract cancer: a prospective phase II trial.BMC medicine · 2026Trial
- Cryoablation with sintilimab and lenvatinib for intrahepatic cholangiocarcinoma: Does the addition of locoregional therapy augment survival outcomes?Hepatobiliary surgery and nutrition · 2026Article
- Effectiveness and safety of PD-1/PD-L1 inhibitors plus lenvatinib with or without Gemox chemotherapy in advanced intrahepatic cholangiocarcinoma.BMC cancer · 2026Article
- Predictive Immunohistochemistry in Cholangiocarcinoma: Current Clinical Utility, Practical Limitations, and Emerging Directions.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Review
- Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma.Discover oncology · 2025Article
- The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study.Current oncology (Toronto, Ont.) · 2025Article
- Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer.Current treatment options in oncology · 2024Review
- A case report: deep and durable response to low-dose lenvatinib and tislelizumab in an elderly patient with advanced intrahepatic cholangiocarcinoma.Frontiers in pharmacology · 2024Article
- Hepatic arterial infusion chemotherapy in combination with lenvatinib and durvalumab versus standard first-line treatment gemcitabine and cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma.American journal of cancer research · 2024Article
- Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.Frontiers in immunology · 2024Article
- Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case.Frontiers in oncology · 2024Article
- Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study.Frontiers in immunology · 2023Article
- Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma.Frontiers in oncology · 2023Article
- Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.Frontiers in immunology · 2023Article
- M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma.Frontiers in immunology · 2023Article
- Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Lulu XieDepartment of Minimally Invasive Interventional Radiology and Department of Radiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jingzheng HuangDepartment of Minimally Invasive Interventional Radiology and Department of Radiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Linling WangDepartment of Minimally Invasive Interventional Radiology and Department of Radiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Wenrui RenDepartment of Minimally Invasive Interventional Radiology and Department of Radiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Hao TianDepartment of Minimally Invasive Interventional Radiology and Department of Radiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Anhong HuDepartment of Minimally Invasive Interventional Radiology and Department of Radiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jun LiangDepartment of Minimally Invasive Interventional Radiology and Department of Radiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yuqing JiaoDepartment of Minimally Invasive Interventional Radiology and Department of Radiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yali LiDepartment of Minimally Invasive Interventional Radiology and Department of Radiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Qunfang ZhouDepartment of Minimally Invasive Interventional Radiology and Department of Radiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Wenjing ZhangDepartment of Ultrasound, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Second Affiliated Hospital of Guangzhou Medical University · CNGuangzhou Medical University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
advanced intrahepatic cholangiocarcinomachemotherapy failurecombination therapylenvatinibPD-1 inhibitor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.